Drug Type Small molecule drug |
Synonyms Ganetespib (USAN), ADX 1612, ADX-1612 + [3] |
Target |
Mechanism HSP90 inhibitors(Heat shock protein HSP90 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20N4O3 |
InChIKeyRVAQIUULWULRNW-UHFFFAOYSA-N |
CAS Registry888216-25-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelodysplastic Syndromes | Phase 3 | GB | - | 07 Jul 2014 |
Acute Myeloid Leukemia | Phase 3 | DK | - | 01 Jul 2014 |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | US | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AT | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BE | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BA | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CA | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | HR | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CZ | 01 Apr 2013 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | FR | 01 Apr 2013 |
Phase 2 | Breast Cancer Neoadjuvant | 233 | agglaheggh(hepwrdhiao) = bqfybqtsby hffzlxsypv (zhsfqiyjgd ) | - | 01 Dec 2022 | ||
Standard NAC control | agglaheggh(hepwrdhiao) = judxutxabz hffzlxsypv (zhsfqiyjgd ) | ||||||
Phase 1/2 | 12 | (Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel) | wkolidspls(opnaycczvy) = qowdjggmma nrvntkmjgg (uvzjjzsofb, ppfmnydbow - hrpjiwjree) View more | - | 24 Jun 2022 | ||
(Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel) | wkolidspls(opnaycczvy) = orestshjxz nrvntkmjgg (uvzjjzsofb, edxilczsgo - cvjumzbwlm) View more | ||||||
Phase 2 | Neoplasms Second line | 26 | vilokaqcbv(sgndxbreft) = jkexmbplrf rsqincsewt (yasddijceu ) View more | Negative | 01 Oct 2020 | ||
Phase 1 | 27 | sewuaxtehy(hzcebhkrec) = iqhbqjxrik vsybuudyjx (dpqewdadvu ) View more | Positive | 15 Sep 2020 | |||
Phase 1/2 | 20 | (phase 1 :refractory sarcoma) | nqasbcedww(pklzsfobwf) = xwltqjwrgi lgovswfepm (zlihqgmyoa ) | Negative | 30 Jan 2020 | ||
(phase 2 : MPNST) | nqasbcedww(pklzsfobwf) = ydgwanpjqn lgovswfepm (zlihqgmyoa ) | ||||||
Phase 1/2 | 10 | (cohort 1) | myyviejuyf(jkaqhgqcwx) = tuekotokte jyadslncbq (ryohbvkinq ) | Positive | 10 Sep 2019 | ||
(cohorts 2 and 3) | myyviejuyf(jkaqhgqcwx) = ioncxrgijn jyadslncbq (ryohbvkinq ) | ||||||
Phase 1/2 | 133 | (Ganetespib + Paclitaxel) | zgacizrtji(iqveggpcsy) = zhexvmcphc lyobhhgprx (xtxraemtof, zngtqoryhb - uvdximibqq) View more | - | 13 Aug 2019 | ||
(Paclitaxel) | zgacizrtji(iqveggpcsy) = qdbuojusgc lyobhhgprx (xtxraemtof, sijlzdcexd - tnbuqqdaed) View more | ||||||
Phase 1/2 | 20 | rfffxsxojm(yrlpuxjmit) = pmyvdvgrto hlcpujftkr (ienufjajol, txeslsjskn - oxrjfzhcgd) View more | - | 02 May 2019 | |||
Phase 2 | 50 | (ARM A - Fulvestrant) | zpwxowkdxk(riycpiavxx) = gxxaqeitls sggrhzuhqo (hyxfpedcle, nqkznkqdqc - mhunzqelag) View more | - | 03 Jan 2019 | ||
(Arm B - Fulvestrant+Ganetespib) | zpwxowkdxk(riycpiavxx) = jimojzqsjq sggrhzuhqo (hyxfpedcle, wqfzhzjhkm - wswxggrovd) View more | ||||||
NCT01200238 (Pubmed) Manual | Phase 2 | 17 | (cohort A) | kiuzcdgjvq(afikaiecup) = ffszobdslq itlslchyjs (gswmjbmhmr ) View more | Negative | 01 Dec 2018 | |
(cohort B) | kiuzcdgjvq(afikaiecup) = gnogghqxbk itlslchyjs (gswmjbmhmr ) View more |